Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA): 6 pipeline candidates · 3 upcoming catalysts · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.8 months
D/E 0.24 · 8% dilution
Lead: Phase 1/Phase 2
6 candidates
3 upcoming, next in ~12d
1 buy · 8 sells (180d)
A transparent, data-derived signal for Entrada Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$255.2M
Cash
$79.7M
Quarterly Burn
$41.7M
Runway
9.8 mo
Revenue
$875K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| entr-601-44 | Phase 1/Phase 2 |
| entr-601-45 | Phase 1/Phase 2 |
| entr-601-50 | Phase 1/Phase 2 |
| entr-601-51 | Phase 1/Phase 2 |
| entr-801 | Phase 1/Phase 2 |
| vx-670 | Phase 1/Phase 2 |
Upcoming Catalysts (3)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
116
Total value held
$239.7M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 5,072,730 | $64.0M |
| vanguard capital management llc | 2,512,026 | $31.7M |
| blackrock, inc. | 2,358,793 | $29.8M |
| wellington management group llp | 1,034,782 | $13.1M |
| geode capital management, llc | 667,347 | $8.4M |
| state street corp | 533,798 | $6.7M |
| millennium management llc | 519,356 | $6.6M |
| woodline partners lp | 431,954 | $5.5M |
| jones hill capital lp | 374,010 | $4.7M |
| jacobs levy equity management, inc | 333,914 | $4.2M |
Showing top 10 of 116 institutional holders of Entrada Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Entrada Therapeutics, Inc.'s pipeline?
Entrada Therapeutics, Inc. (TRDA) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Entrada Therapeutics, Inc.'s lead drug candidate?
Entrada Therapeutics, Inc.'s most advanced tracked candidate is entr-601-44 (Phase 1/Phase 2) for Duchenne Muscular Dystrophy (DMD).
What is Entrada Therapeutics, Inc.'s next catalyst?
Entrada Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pipeline candidate" — expected June 30, 2026.
What is Entrada Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Entrada Therapeutics, Inc. has approximately 9.8 months of cash runway.
What is Entrada Therapeutics, Inc.'s market capitalization?
Entrada Therapeutics, Inc.'s market capitalization is approximately $255.2M.
Get the full picture on Entrada Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.